Skip to content

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00044226
Enrollment
350
Registered
2002-08-23
Start date
2002-04-30
Completion date
2002-10-31
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Keywords

BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Enlarged Prostate

Brief summary

Patients who are currently symptomatic and have been diagnosed with BPH by a physician may qualify for this 20-week study. Patients must not be diabetic, must not have prostate cancer and must not have had any surgery to repair your prostate or treat your BPH. Patients will first undergo a phone screening to confirm their eligibility and interest and to rule out any exclusionary history or medications. Eligible patients will be scheduled to come in to the clinic to sign an Informed Consent Form. Patients will then undergo blood and urine tests, a complete physical examination and history and answer several questionnaires to determine their eligibility. Patients will have a total of at least 7-8 visits over 20 weeks to the clinic during this study.Qualified patients receive free study medication, free medical care (physical examinations, EKG, laboratory tests) for the duration of the study.

Detailed description

Patients must be willing to discontinue their current medications being taken for BPH for specified time periods before they become eligible. These include: Proscar, Saw Palmetto, and any alpha-blocker drugs. Patients with high blood pressure must be on an acceptable medication that controls this condition. Medications for other conditions may disqualify a patient from eligibility.Patients who are diabetic are not eligible for this study. All patients will, at some time during the study, receive placebo (inactive substance). The study medication is given twice a day in liquid form under the tongue. There is a 33% chance that you would receive placebo for the duration of the study. Neither you nor your doctor will know which treatment you are receiving.

Interventions

DRUGML-04A

Sponsors

Milkhaus Laboratory
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
MALE
Age
45 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Have an enlarged prostate by DRE (digital rectal examination); * Have a diagnosis of BPH; * Have documented symptoms (frequency; urgency; nighttime urination; reduced flow); * Have a documented urinary flow rate as required

Countries

United States

Contacts

Primary ContactMartha J. DuRuz-Lynch, BA
414.425.6566

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026